Proprio is a computational imaging company providing enhanced visualization systems for precise surgical execution. The Proprio system integrates advancements in robotics, artificial intelligence, and computer vision to simplify surgical workflow, improve procedural accuracy, and reduce or eliminate radiation exposure
Fremont, CA: surgical Navigation Company Proprio raised USD 23 million in a Series A funding round led by DCVC (Data Collective) with additional investment from Cota Capital. The round was also participated by existing investors BOLD Capital Partners and Alan Frazier, founder of East Seattle Partners and Frazier Healthcare Partners. "Proprio's mission is to improve the precision and efficiency of surgery," said Gabriel Jones, CEO, and Co-founder of Proprio. "This investment supports our world-class team to deliver a surgical navigation system that leverages the latest technological advancements in imaging and machine learning, making it easier to perform high-quality surgeries."
Proprio is a computational imaging company providing enhanced visualization systems for precise surgical execution. The Proprio system integrates advancements in robotics, artificial intelligence, and computer vision to simplify surgical workflow, improve procedural accuracy, and reduce or eliminate radiation exposure. This helps to increase surgical productivity while enhancing the precision of surgery. As medical institutions tackle the COVID-19 pandemic, there is an increasing amount of backlog cases. Two critical factors affecting these backlogs are an upcoming shortage of 23,400 surgical specialists in the U.S. and physician burnout, which costs USD 4.6 billion annually. By improving near term benefits to surgeons and medical institutions, the company's platform also creates valuable new data sets to enhance clinical capability over the long term. 
"As a cerebrovascular neurosurgeon, I am interested in the potential to use Proprio's system to navigate and digitize the entire surgical experience," said Dr. Christopher Kellner, a neurosurgeon at Mount Sinai in New York City. "It will let surgeons detect nuances that we wouldn't have noticed otherwise -- creating a new level of first-hand observation that would help us continuously learn and perfect our craft." Along with the Series A investment round, the company also added Armen Vidian, a DCVC partner with extensive operational experience in healthcare and medical devices, including early market development for first-in-class technologies, to its board of directors. Also joining as Board Observer is Alan Cohen, a DCVC partner with broad expertise in product development and go-to-market strategy for multiple billion-dollar companies.
"Proprio is creating the most transformative technology in surgery since the X-ray," said Armen Vidian, Partner at DCVC. "DCVC has invested in Gabriel and his tremendous team, which includes proven leaders in artificial intelligence, computer vision, medical devices, and clinical medicine because we believe they are uniquely qualified to execute on this ambitious goal."
